Matches in SemOpenAlex for { <https://semopenalex.org/work/W4301166056> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W4301166056 endingPage "416" @default.
- W4301166056 startingPage "393" @default.
- W4301166056 abstract "The paper reviews the current strategic approach of the Istituto Nazionale Tumori of Milan with adriamycin (ADM) in combination with other drugs as well as in combined treatment modalities for various neoplasias of adults and children. The preliminary results obtained during the past four years in malignant lymphomas, acute leukemias, carcinoma of the breast, and neuroblastoma are reported. With the exception of the group of malignant lymphomas treated with a quintuple drug regimen (MABOP), none of the patients admitted the different trials had received chemotherapy. Most studies were controlled with random allocation to two different combinations. Cross over was carried out on relapse. In advanced Hodgkin's disease, non-Hodgkin's lymphomas, mammary carcinoma, soft tissue sarcomas, embryonal carcinoma of testicle, ovarian carcinoma, and multiple myeloma the main purpose of the study was to develop two independent non cross resistant combinations to be used sequentially in subsequent trials. There is a preliminary evidence that this is being obtained in Hodgkin's disease (ABVD vs. MOPP), in non Hodgkin's lymphomas (ABP vs. CVP) and carcinoma of the breast (ADM + VCR vs. CMF). In the other groups the patients were too few to permit conclusions. In acute lymphoblastic leukemia, in the leukemic phase of non-Hodgkin's lymphomas as well as in the group of solid tumors of children, combination chemotherapy and combined treatment modalities were not designed in a controlled fashion. ADM was introduced in all treatments because of its definite activity when employed as a single agent in refractory disease. Few therapeutic results are as yet available since most studies were started in 1974. However, the remission rate observed in the limited group of acute leukemias treated with ADM + VCR + prednisone is worth noting. The wide spectrum of activity of ADM justifies its use in several protocols of combination chemotherapy and in combined treatment modalities. With both full and reduced regimens drug tolerance was good, and in practically all studies more than 80 % of the optimal dose of ADM could be administered. All trials were properly designed to avoid a total dose of ADM exceeding 550–600 mg/m 2 since cardiomyopathy (reversible) was observed in 2 patients after 600 mg/m 2 ." @default.
- W4301166056 created "2022-10-04" @default.
- W4301166056 creator A5004757300 @default.
- W4301166056 creator A5015952023 @default.
- W4301166056 creator A5023558260 @default.
- W4301166056 creator A5030301955 @default.
- W4301166056 creator A5051722602 @default.
- W4301166056 creator A5065678804 @default.
- W4301166056 creator A5067094608 @default.
- W4301166056 creator A5070704228 @default.
- W4301166056 creator A5087428107 @default.
- W4301166056 date "1974-09-01" @default.
- W4301166056 modified "2023-09-25" @default.
- W4301166056 title "Adriamycin in Combination and in Combined Treatment Modalities." @default.
- W4301166056 cites W2020893327 @default.
- W4301166056 cites W2024841231 @default.
- W4301166056 cites W2034359426 @default.
- W4301166056 cites W2064722407 @default.
- W4301166056 cites W2084145198 @default.
- W4301166056 cites W2092015388 @default.
- W4301166056 cites W2277918015 @default.
- W4301166056 doi "https://doi.org/10.1177/030089167406000505" @default.
- W4301166056 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/4142149" @default.
- W4301166056 hasPublicationYear "1974" @default.
- W4301166056 type Work @default.
- W4301166056 citedByCount "3" @default.
- W4301166056 countsByYear W43011660562014 @default.
- W4301166056 crossrefType "journal-article" @default.
- W4301166056 hasAuthorship W4301166056A5004757300 @default.
- W4301166056 hasAuthorship W4301166056A5015952023 @default.
- W4301166056 hasAuthorship W4301166056A5023558260 @default.
- W4301166056 hasAuthorship W4301166056A5030301955 @default.
- W4301166056 hasAuthorship W4301166056A5051722602 @default.
- W4301166056 hasAuthorship W4301166056A5065678804 @default.
- W4301166056 hasAuthorship W4301166056A5067094608 @default.
- W4301166056 hasAuthorship W4301166056A5070704228 @default.
- W4301166056 hasAuthorship W4301166056A5087428107 @default.
- W4301166056 hasConcept C121608353 @default.
- W4301166056 hasConcept C126322002 @default.
- W4301166056 hasConcept C143998085 @default.
- W4301166056 hasConcept C2776305933 @default.
- W4301166056 hasConcept C2776694085 @default.
- W4301166056 hasConcept C2776755627 @default.
- W4301166056 hasConcept C2779134260 @default.
- W4301166056 hasConcept C2779338263 @default.
- W4301166056 hasConcept C2779429289 @default.
- W4301166056 hasConcept C3018521938 @default.
- W4301166056 hasConcept C530470458 @default.
- W4301166056 hasConcept C71924100 @default.
- W4301166056 hasConceptScore W4301166056C121608353 @default.
- W4301166056 hasConceptScore W4301166056C126322002 @default.
- W4301166056 hasConceptScore W4301166056C143998085 @default.
- W4301166056 hasConceptScore W4301166056C2776305933 @default.
- W4301166056 hasConceptScore W4301166056C2776694085 @default.
- W4301166056 hasConceptScore W4301166056C2776755627 @default.
- W4301166056 hasConceptScore W4301166056C2779134260 @default.
- W4301166056 hasConceptScore W4301166056C2779338263 @default.
- W4301166056 hasConceptScore W4301166056C2779429289 @default.
- W4301166056 hasConceptScore W4301166056C3018521938 @default.
- W4301166056 hasConceptScore W4301166056C530470458 @default.
- W4301166056 hasConceptScore W4301166056C71924100 @default.
- W4301166056 hasIssue "5" @default.
- W4301166056 hasLocation W43011660561 @default.
- W4301166056 hasLocation W43011660562 @default.
- W4301166056 hasOpenAccess W4301166056 @default.
- W4301166056 hasPrimaryLocation W43011660561 @default.
- W4301166056 hasRelatedWork W110850012 @default.
- W4301166056 hasRelatedWork W160156331 @default.
- W4301166056 hasRelatedWork W2040074407 @default.
- W4301166056 hasRelatedWork W2050219139 @default.
- W4301166056 hasRelatedWork W2158035792 @default.
- W4301166056 hasRelatedWork W2178567417 @default.
- W4301166056 hasRelatedWork W2363198604 @default.
- W4301166056 hasRelatedWork W2368014424 @default.
- W4301166056 hasRelatedWork W2442023154 @default.
- W4301166056 hasRelatedWork W2183308400 @default.
- W4301166056 hasVolume "60" @default.
- W4301166056 isParatext "false" @default.
- W4301166056 isRetracted "false" @default.
- W4301166056 workType "article" @default.